Docosahexaenoic Acid (DHA) Supplementation in Pregnancy to Reduce Early Preterm Birth

孕期补充二十二碳六烯酸 (DHA) 可减少早期早产

• 批准号: 9029454
• 负责人: SUSAN E CARLSON
• 金额: $ 67.03万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-01-19 至 2020-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9029454
• 关键词: Acids; Address; Adult; Adverse event; Affect; Attenuated; Australia; Bayesian Modeling; Birth; Birth Weight; Cesarean section; Clinical Trials; Community Practice; Community of Practice; Control Groups; Corn Oil; Country; Data; Diet; Docosahexaenoic Acids; Dose; Double-Blind Method; Family; Fishes; Formulation; Gender; Gestational Diabetes; Goals; Incidence; Income; Infant; Infant Mortality; Inflammation; Inflammatory; Intake; Intervention; Knowledge; Modeling; Nutrient; Oils; Outcome; Participant; Phase III Clinical Trials; Placebo Control; Placebos; Plasma; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Pregnancy Trimesters; Pregnant Women; Premature Birth; Prenatal Nutrition; Probability; Public Health; Public Policy; Randomized; Research; Risk; Safety; Sample Size; Schedule; Site; Smoking; Societies; Soybean Oil; Supplementation; Testing; Umbilical Cord Blood; United States; Woman; alpha-Linolenic Acid; base; capsule; clinical practice; cohort; cost; design; dietary supplements; effective therapy; infant morbidity/mortality; inhibitor/antagonist; intraamniotic infection; mouse model; novel; nutritional supplementation; phase III trial; placebo controlled study; pregnant; prenatal; public health relevance; randomized trial; response; secondary outcome

 DESCRIPTION (provided by applicant): DHA intake of US adults is low and conversion of α-linolenic acid (18:3n-3) to DHA (22:6n-3) is also low. As a result US women enter pregnancy with lower DHA status than other countries in the developed world suggesting a potential deficiency of an important nutrient that has been shown to reduce inflammation. The goal of this Phase III Clinical Trial (randomized, double-blind, and placebo-controlled) is to test the primary hypothesis that supplementing US women with 1000 mg of docosahexaenoic acid (DHA), 800 mg above the amount currently in many prenatal nutritional supplements (~200 mg) during the half of pregnancy can reduce early preterm birth (ePTB) (<34 wk. gestation). This was a favorable secondary outcomes of a US trial (RO1 HD047315, Clinical Trials.gov ID: NCT00266825) conducted at one of the proposed study sites on which the current proposal is modeled. Secondary outcomes include birth weight <1500g and pregnancy outcomes (preeclampsia, gestational diabetes, C-section delivery). We propose a Bayesian Adaptive Design with 90% power to detect the hypothesized outcomes with an estimated 938 subjects that allows the study to stop early if strong results (probability >0.995) are observed before the study is scheduled to end and places 60% of the participants on the better DHA dose. Conventional equal randomization with 90% power would require 1200 subjects, be longer, and place only 50% of the participants on the better DHA dose. The proposed study has the potential to determine if nutritional supplementation with DHA during pregnancy can reduce the incidence of ePTB, a serious public health problem with large societal and family costs. The randomization design has the potential to significantly expedite findings to the research community and clinical practice.